CMA removes barrier to availability of vital treatments on the NHS

News Competition English Statements & Speeches

Date: 17th Nov, 2023 Source: Competition and Markets Authority Country: United Kingdom Original Source

Brief

iStock The Competition and Markets Authority (CMA) has today issued a statement clarifying that certain types of engagements between competing drug firms working on ‘combination therapies’ will not be prioritised for investigation – making it easier for drug firms to work together to develop vital treatments for use in the NHS. The CMA’s statement comes

Hello!

To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.

Go to Home Page

Highlights content goes here...

Hello!

To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.

Go to Home Page

Competition and Markets Authority

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

CMA removes barrier to availability of vital treatments on the NHS

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

CMA removes barrier to availability of vital treatments on the NHS

Brief

Competition and Markets Authority

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.